Literature DB >> 22306837

Recommendation for standardized surgical management of primary adrenocortical carcinoma.

Sébastien Gaujoux1, Murray F Brennan.   

Abstract

BACKGROUND: Operative resection is the only potentially curative treatment for primary adrenocortical carcinoma (ACC), but standards of operative care are not defined with regards to the extent of local resection. We propose recommendations for operative management.
METHODS: Anatomic and clinical literature review focusing on local management of ACC, including lymphadenectomy and resection of adjacent organs or large vessels.
RESULTS: First-order drainage nodes of the adrenal gland include the renal hilum lymph nodes, the celiac lymph nodes, and the para-aortic and paracaval lymph nodes, mainly above the renal pedicle and ipsilateral to the adrenal glands. Lymph node involvement occurs in about 20% of patients with ACC, and is an important prognostic factor, but lymphadenectomy is performed infrequently. The adrenal glands and kidneys are contained in the same anatomic space, but systematic en bloc nephrectomy has no proven benefits for survival. Direct invasion of the kidney or adjacent organs is rare, but major venous invasion with tumor thrombus is relatively common. Both are associated with decreased survival, but complete resection can lead to long-term survival.
CONCLUSION: Standardization of regional lymphadenectomy including first-order drainage nodes is proposed. Systematic nephrectomy is not necessary in the absence of gross local invasion, but locally involved organs or large veins should be resected en bloc, with tumor thrombus embolectomy, if R0 resection is possible. Operative standardization improves tumor staging, potentially decreases local recurrence, and may be associated with better survival. Evidence-based standards of operative care and prospective investigations within international collaborating groups are necessary.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22306837     DOI: 10.1016/j.surg.2011.09.030

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  13 in total

1.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

Review 2.  Surgical management of adrenocortical tumours.

Authors:  Barbra S Miller; Gerard M Doherty
Journal:  Nat Rev Endocrinol       Date:  2014-03-18       Impact factor: 43.330

3.  Does Lymphadenectomy Improve Survival in Patients with Adrenocortical Carcinoma? A Population-Based Study.

Authors:  Naris Nilubol; Dhaval Patel; Electron Kebebew
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

Review 4.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

5.  Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?

Authors:  F Porpiglia; C Fiori; F C Daffara; B Zaggia; A Ardito; R M Scarpa; M Papotti; A Berruti; G V Scagliotti; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-12-22       Impact factor: 4.256

6.  Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes.

Authors:  Georgios Antonios Margonis; Yuhree Kim; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2015-08-19       Impact factor: 5.344

Review 7.  [German adrenocortical carcinoma registry. Surgical therapy results and follow-up treatment].

Authors:  J Reibetanz; M Kroiss; T Deutschbein; W Fenske; M Gasser; C Jurowich; C-T Germer; B Allolio; M Fassnacht
Journal:  Chirurg       Date:  2012-06       Impact factor: 0.955

8.  Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database.

Authors:  Paula Marincola Smith; Colleen M Kiernan; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason Prescott; Timothy Pawlik; Tracy S Wang; Jason Glenn; Ioannis Hatzaras; Rivka Shenoy; John Phay; Lawrence A Shirley; Ryan C Fields; Linda Jin; Sharon Weber; Ahmed Salem; Jason Sicklick; Shady Gad; Adam Yopp; John Mansour; Quan-Yang Duh; Natalie Seiser; Konstantinos Votanopoulos; Edward A Levine; George Poultsides; Carmen C Solórzano
Journal:  Ann Surg Oncol       Date:  2018-06-04       Impact factor: 5.344

9.  Adrenocortical carcinoma: modern management and evolving treatment strategies.

Authors:  Lucas A McDuffie; Rachel D Aufforth
Journal:  Int J Endocr Oncol       Date:  2016-04-08

10.  The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.

Authors:  Raffaele Pezzani; Beatrice Rubin; Loris Bertazza; Marco Redaelli; Susi Barollo; Halenya Monticelli; Enke Baldini; Caterina Mian; Carla Mucignat; Carla Scaroni; Franco Mantero; Salvatore Ulisse; Maurizio Iacobone; Marco Boscaro
Journal:  Invest New Drugs       Date:  2016-05-14       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.